Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Human Albumin 2% Clear all
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211
View directory record Official record
Conditions
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
30
States / cities
Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 17, 2026, 4:18 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

hCT-MSCs for COVID19 ARDS

NCT04399889
View directory record Official record
Conditions
COVID, Corona Virus Infection, COVID19
Interventions
Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo
Biological · Other
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Boca Raton, Florida • Miami, Florida • Valhalla, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 17, 2026, 4:18 AM EDT
Not listed Phase 1 Interventional

Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.

NCT04839991
View directory record Official record
Conditions
Advanced and/or Metastatic Solid Tumours
Interventions
CB307
Drug
Lead sponsor
Crescendo Biologics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 17, 2026, 4:18 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

NCT04044690
View directory record Official record
Conditions
Dermatomyositis
Interventions
human immunoglobulin G, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
15
States / cities
Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

NCT04104672
View directory record Official record
Conditions
Advanced Pancreatic Cancer
Interventions
AB680, Zimberelimab, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Santa Monica, California • St Louis, Missouri • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 17, 2026, 4:18 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

NCT03387111
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Aldoxorubicin HCl, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for infusion, Avelumab, bevacizumab, Capecitabine, Cetuximab, Cisplatin, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, Necitumumab, SBRT, N-803
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2024 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

NCT02158520
View directory record Official record
Conditions
Metastatic Melanoma, Mucosal Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7, Unresectable Melanoma
Interventions
Bevacizumab, Ipilimumab, Laboratory Biomarker Analysis, Nab-paclitaxel, Pharmacological Study
Biological · Other · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
13
States / cities
San Francisco, California • Jacksonville, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)

NCT00684060
View directory record Official record
Conditions
Left Ventricular Dysfunction
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Sep 17, 2026, 4:18 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of SPM™ Topical Cosmetic Application on Skin Appearance, Hydration, and Barrier Support in Healthy Adults

NCT07236736
View directory record Official record
Conditions
Healthy Skin, Skin Hydration
Interventions
Skin biopsy, Corneometer® Measurement, Tewameter® Measurement
Procedure · Other
Lead sponsor
Biocoz Global Pte. Ltd.
Industry
Eligibility
20 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 17, 2026, 4:18 AM EDT
Active, not recruiting Phase 2 Interventional

A Trial of Vigil for Participants With Ovarian Cancer

NCT02346747
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Neoplasms
Interventions
Vigil, Placebo
Biological · Other
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
26
States / cities
Mobile, Alabama • Irvine, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 1Phase 2 Interventional

IVIG - West Nile Encephalitis: Safety and Efficacy

NCT00068055
View directory record Official record
Conditions
West Nile Virus
Interventions
Omr-lgG-am, Polygam® S/D, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2011 · Synced Sep 17, 2026, 4:18 AM EDT
Recruiting Phase 2 Interventional

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

NCT05325632
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
HER-2 pulsed DC1, Trastuzumab, Pertuzumab, Paclitaxel, Resection surgery
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 17, 2026, 4:18 AM EDT
Active, not recruiting Phase 1 Interventional

Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors

NCT05352750
View directory record Official record
Conditions
Advanced Solid Tumor, Soft Tissue Sarcoma Adult
Interventions
SON-1010
Biological
Lead sponsor
Sonnet BioTherapeutics
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 17, 2026, 4:18 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

NCT03387098
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Aldoxorubicin HCl, ALT-803, ETBX-011, GI-4000, haNK for infusion, avelumab, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, lovaza, Oxaliplatin, SBRT
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

NCT01839487
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
PEGPH20, Nab-paclitaxel, Gemcitabine, Dexamethasone, Enoxaparin
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
51
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 1 Interventional

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

NCT03554044
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
Interventions
Anastrozole, Exemestane, Fulvestrant, Letrozole, Paclitaxel, Talimogene Laherparepvec, Tamoxifen, Nab paclitaxel, Gemcitabine, Carboplatin
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye

NCT01843894
View directory record Official record
Conditions
Dry Eye
Interventions
RU-101
Biological
Lead sponsor
R-Tech Ueno, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 17, 2026, 4:18 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer

NCT07705919
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fluorouracil, Gadolinium-Chelate, Gemcitabine, Irinotecan, Leucovorin Calcium, Nab-paclitaxel, Oxaliplatin, Point-of-care portable perfusion phantom (P4)
Procedure · Drug · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 17, 2026, 4:18 AM EDT
Terminated Phase 3 Interventional Results available

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

NCT02097121
View directory record Official record
Conditions
Urinary Incontinence, Urinary Bladder, Overactive
Interventions
BOTOX®
Biological
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
8
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

NCT00818662
View directory record Official record
Conditions
Alzheimer´s Disease
Interventions
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg, Placebo solution: Human Albumin 0.25% - 4 mL/kg, Placebo solution: Human Albumin 0.25% - 2 mL/kg
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
50 Years to 89 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 17, 2026, 4:18 AM EDT
Recruiting Phase 2 Interventional

Belimumab With Rituximab for Primary Membranous Nephropathy

NCT03949855
View directory record Official record
Conditions
Membranous Nephropathy, Nephrotic Syndrome
Interventions
Belimumab, Placebo for Belimumab, Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

NCT02015091
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 17, 2026, 4:18 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

NCT03387085
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for Infusion, avelumab, bevacizumab, Capecitabine, Cisplatin, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, SBRT
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 17, 2026, 4:18 AM EDT
Completed Phase 1 Interventional

Laser Tissue Welding - Distal Pancreatectomy Sealing Study

NCT03147768
View directory record Official record
Conditions
Pancreatic Tumor, Benign, Pancreatic Neoplasms, Pancreatic Adenocarcinoma, Pancreatic Pseudocyst, Pancreatic Neuroendocrine Tumor, Pancreas; Insulinoma, Pancreatic Cyst, Pancreatic Teratoma, Pancreatic Polypeptide Tumor, Pancreatic Vipoma, Pancreatic Cystadenoma, Pancreas Injury, Pancreatic Gastrinoma, Pancreatic Glucagonoma
Interventions
Distal Pancreatectomy Sealing Using LTW
Device
Lead sponsor
Laser Tissue Welding, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Sep 17, 2026, 4:18 AM EDT